An observational study in Cataract, sponsored by Berkeley Eye Center. Completed at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Berkeley Eye Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.
Among the 456 studies in Cataract with a site in United States, this one is the 64th largest by enrollment of the 128 observational ones that give a count, is one of 28 that started in 2023, is one of 128 observational ones, and was the 438th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eric Rosenberg · Sites in United States
Ages 18–90
The Eye Institute of West Florida · Sites in United States
Ages 40+
Gainesville Eye Associates · Sites in United States
Ages 18+
Laser Defined Vision · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
456 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 25 · Phase 3 59 · Phase 4 86
First in 1987; this study’s year is marked. 28 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 90 across 476 observational studies indexed under Cataract.
Median enrollment 100 across the 322 interventional studies, 61 across the 128 observational. Of the 365 that completed or were terminated, 177 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
239 of 456 have an industry lead sponsor. The 10 most frequent:
Berkeley Eye Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Berkeley Eye Center has 3 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
21 of the studies in Cataract with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07898917Gainesville Eye AssociatesPureSee/Odyssey Mix-and-Match IOL | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07260695Center For SightOdyssey Evaluation in Post LASIK Patients | 2026-12-18 |
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 456 studies in Cataract with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, ambispective, observational study evaluates axial length acquisition in eyes with dense cataracts using the ARGOS swept-source optical coherence tomography biometer compared with the IOLMaster 700. Eligible subjects are pseudophakic adults who previously underwent complex cataract surgery because of poor visualization or poor red reflex from dense lens opacity and who had pre-operative biometry performed with both devices, with or without manual immersion A-scan ultrasonography. Enrolled subjects return for postoperative repeat biometry to confirm pre-operative measurements and to assess whether availability of an ARGOS axial length measurement may reduce the need for manual ultrasound A-scans in similar dense cataract cases. The planned sample size justification estimated that 61 patients were needed for statistical power, while 68 were originally targeted to allow for attrition in the prospective portion.
Cataract surgery is the most commonly performed surgical procedure in the United States. Accurate axial length measurement is critical for intraocular lens power selection, but optical biometry can be challenging in eyes with dense cataracts because of poor media penetration and limited signal acquisition. When optical axial length measurement cannot be obtained, manual immersion A-scan ultrasonography is often required, which adds workflow complexity, technician time, and patient time.
This study was designed to evaluate the performance of the ARGOS swept-source optical coherence tomography biometer in eyes with dense cataracts and to compare its axial length acquisition capability with that of the IOLMaster 700. The study also evaluates whether use of ARGOS, including enhanced retina visualization mode when needed, may reduce reliance on manual ultrasound biometry in this setting.
This is a single-center, ambispective, non-interventional observational study. The retrospective component involves review of prior cataract surgery cases in which pre-operative biometry had been performed with both the ARGOS and the IOLMaster 700 in eyes with dense cataracts associated with poor visualization or poor red reflex. The prospective component consists of a postoperative study visit in enrolled subjects for repeat biometry, allowing comparison of postoperative measurements with historical pre-operative values and assessment of whether successful ARGOS measurement could have reduced the need for confirmatory ultrasound testing.
The overall purpose of the study is to better characterize the utility of ARGOS biometry in dense cataracts and to assess its potential clinical value in reducing the need for manual A-scan ultrasonography in routine practice.
Pseudophakic adults who previously underwent complex cataract surgery for poor red reflex or poor visualization due to dense cataract and had pre-operative biometry with both the ARGOS and IOLMaster 700.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pseudophakic adult subjects who previously underwent complex cataract surgery because of poor visualization or poor red reflex from dense cataract and who had pre-operative biometry performed with the ARGOS and IOLMaster 700, with or without manual immersion A-scan ultrasonography. Enrolled subjects undergo postoperative repeat biometry for comparison with pre-operative measurements.
Diagnostic Test: ARGOS biometer · Diagnostic Test: IOLMaster 700
Swept-source optical coherence tomography biometer used for axial length measurement pre-operatively and at the postoperative study visit. Enhanced retina visualization mode may be used when needed.
Swept-source optical coherence tomography biometer used for axial length measurement pre-operatively and at the postoperative study visit for comparison with ARGOS measurements.
Percentage of eyes with successful axial length acquisition
Percentage of eyes in which axial length measurements were successfully acquired using the ARGOS biometer compared with the IOLMaster 700 in eyes with dense cataracts.
Time frame: Pre-operative assessment and postoperative confirmation visit, up to 24 months after cataract surgery.
Percentage of eyes requiring ultrasound A-scan
Percentage of eyes that required manual ultrasound A-scan because axial length measurement could not be obtained by optical biometry.
Time frame: Pre-operative review and postoperative confirmation visit, up to 24 months after cataract surgery.
Percentage of eyes requiring enhanced retina visualization mode
Percentage of eyes in which enhanced retina visualization (ERV) mode was required to obtain axial length measurement.
Time frame: Pre-operative review and postoperative confirmation visit, up to 24 months after cataract surgery.
Difference between postoperative and pre-operative axial length measurements
Difference between postoperative axial length measurements and pre-operative axial length measurements for ARGOS and IOLMaster 700.
Time frame: Up to 24 months postoperatively.
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Oct 2025, 24 months.
Of 168 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 24 months is above that.
Counting every sponsor, half of 235 studies reached it within 16 months; a quarter within 9 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Berkeley Eye Center